Amino-salicylate drugs are anti-inflammatory agents used to treat some forms of arthritis such as juvvenile rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis; inflammatory bowel disease such as Crohn’s disease, lymphocytic colitis, ulcerative colitis, ulcerative proctitis; and other ailments such as alopecia and uveitis. The production of interleukin-1, platelet-activating factor synthetase, thromboxane synthetase, prostaglandin, and cyclooxygenase are inhibited by 5-aminosalicylates drugs. These drugs inhibit the acute inflammatory response in patients suffering from inflammatory bowel disease. The 5-aminosalicylates drugs reduce the production of immunoglobulin by plasma cells.
Alopecia is a condition where the patient experiences complete or partial hair loss from areas of the body, where it normally grows. Ankylosing spondylitis is a type of spinal arthritis that occurs in younger males, that eventually causes ankylosis of vertebrae and sacroiliac joints. Crohn’s disease is a chronic intestinal disease that causes inflammation, especially in the ileum and colon, and is associated with fistulae and ulcers. Juvenile rheumatoid arthritis causes stiffness and inflammation in joints for more than one and a half months in children under the age of 16 years. Lymphocytic colitis is the inflammation of large intestine (colon) that causes persistent watery diarrhea. Psoriatic arthritis a condition that causes red patches and silvery scales on the skin. Rheumatoid arthritis is a chronic disease that causes inflammation in joints resulting in painful immobility and deformity, especially in the ankles, feet, wrists, and fingers. Ulcerative colitis is a condition which causes long-lasting inflammation and ulcers in the digestive tract. Ulcerative proctitis is ulcerative colitis of the rectum. Uveitis is the inflammation of the uvea.
Rising number of geriatric people across the globe has been the main factor driving the 5-aminosalicylates drugs market. Aging increases the risk of psoriatic arthritis, which is expected to boost the demand for 5-aminosalicylates drugs. However, lack of awareness restraints the market to some extent. According to a study conducted by the Centers for Disease Control and Prevention (CDC), the huge population suffering from psoriatic arthritis did not take symptoms such as reddening and skin rashes seriously. Nearly 10% to 12% of psoriatic arthritis patients opted for diagnosis in the U.S. National Psoriasis Foundation and Celgene have been striving to raise awareness among the people.
The global 5-aminosalicylates drugs market can be segmented based on molecule type, disease type, distribution channel, and region. In terms of molecule type, the market can be categorized into mesalamine, sulfasalazine, balsalazide, and olsalazine. Based on disease type, the 5-aminosalicylates drugs market can be bifurcated into inflammatory bowel disease and arthritis. In terms of distribution channel the market can be classified into retail pharmacies, hospital pharmacies, and online pharmacies.
In terms of geography, the 5-aminosalicylates drugs market can be divided into Asia Pacific, Latin America, Europe, North America, and Middle East & Africa. North America has been dominating the market. Increasing investments in research & development has made it possible for advanced medical facilities for the countries in North America. Presence of leading pharmaceutical companies and rising geriatric population in North America are propelling the global 5-aminosalicylates drugs market. Europe held the second large share of the 5-aminosalicylates drugs market in 2016 followed by Asia Pacific. In North America and Asia Pacific, there has been increase in government initiatives aimed at providing advanced medical facilities, especially in the emerging countries of Asia pacific. Rapid adoption of advanced medical technologies by the pharmaceutical companies, and rising consciousness among patients are boosting the 5-aminosalicylates drugs market. The market in Latin America is expected to expand during the forecast period. The market in Middle East & Africa are anticipated to expand from 2017 to 2025.
Key players of the global 5-aminosalicylates drugs market include Aspen Australia, Warner Chilcott, Shire Plc, Procter & Gamble Co., Perrigo Company plc, and Pfizer, Inc.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.